{
  "items": [
    {
      "title": "IMDELLTRA速 SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS",
      "description": "Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA速 (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3 months; hazard ratio [HR], 0.60; 95% confidence interval [CI]: 0.",
      "published_utc": "2025-06-02T20:04:00",
      "source": "Yahoo",
      "url": "https://finnhub.io/api/news?id=8a16695b518ef42bbd852035eba4515850b7808df4c1927dd53b9a5d97590323",
      "category": "company",
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 134937219,
      "datetime": 1748865840
    },
    {
      "title": "Amgen Announces New Interim Results from the Global Phase 3 Dellphi-304 Trial Showing Imdelltra速 (Tarlatamab-Llle)",
      "description": "Amgen announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA速 reduced the risk of death by 40% and significantly extended median overall survival by more than...",
      "published_utc": "2025-06-02T17:05:28",
      "source": "Finnhub",
      "url": "https://finnhub.io/api/news?id=a7a1221c3818480d79d82982516185537d2f1544959bb9466bdaa4cac6f1e35d",
      "category": "company",
      "image": "",
      "related_symbols": [
        "AMGN"
      ],
      "api_source": "finnhub_company",
      "id": 134938125,
      "datetime": 1748855128
    }
  ]
}